MedTrace Logo

Digital 3D Breast Tomosynthesis Versus 2D in Clinical Evaluation of High Risk Women

NCT02209129 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2014-08-05

No results posted yet for this study

Summary

Patients with a higher breast cancer risk (higher than 17% according to the IBIS calculation) will receive a 2D digital mammography together with a 3D tomosynthesis (so called combo tomo) of both breasts in two views in order to investigate the additional value of tomosynthesis in the diagnosis of breast cancer.

Conditions

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Chantal Van Ongeval, MD,Phd · Universitaire Ziekenhuizen KU Leuven

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-08-31
Completion
2017-08-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02209129 on ClinicalTrials.gov